Chemiphar and Sumitomo Dainippon partner on novel CNS candidate NC-2800
Shares of Nippon Chemiphar (TYO: 4539) shot up 22% to 2,771 yen today, after it disclosed a partnership with fellow Japanese drugmaker Sumitomo Dainippon Pharma (TYO: 4506).
Chemiphar and Sumitomo Dainippon have concluded a collaborative research and development agreement and an option agreement for a novel antidepressant/anxiolytic candidate compound - NC-2800 – which is currently at non-clinical stage, that is under research and development by Chemiphar.
This drug is the subject of the research and development project “Development of innovative mood regulators with a mechanism of action based on activating opioid δ receptors,” which was adopted under the Cyclic Innovation for Clinical Empowerment (CiCLE) program of Japan Agency for Medical Research and Development (AMED) in January 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze